A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

Inclusion Criteria:

• A documented diagnosis of EoE by endoscopic biopsy.

• Baseline endoscopic biopsies with a demonstration on central reading ofintraepithelial eosinophilic infiltration.

• History (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening.

• Body weight ≥40 kg.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Other causes of esophageal eosinophilia or the following conditions:hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (ChurgStrauss syndrome).

• Active Helicobacter pylori infection.

• History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prioresophageal surgery.

• Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mmupper endoscope or any critical esophageal stricture that requires dilation atscreening.

• History of bleeding disorders or esophageal varices.

• Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline.

• Initiation or change of a food elimination diet regimen or reintroduction of apreviously eliminated food group in the 6 weeks prior to screening.

• Participation in prior dupilumab clinical study or participants currently treated orhave been treated with commercially available dupilumab or contraindicated todupilumab per local labelling.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial